RARE – Ultragenyx Pharmaceutical Inc.
Float Short %
9.88
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
0.34
EPS Last/This Y
0.52
EPS This/Next Y
1.31
Price
36.22
Target Price
81.85
Analyst Recom
1.19
Performance Q
24.93
Relative Volume
1.04
Beta
0.12
Ticker: RARE
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-13 | RARE | 32.89 | 0.45 | 0.02 | 67608 |
| 2025-11-14 | RARE | 33.08 | 0.45 | 0.08 | 67724 |
| 2025-11-17 | RARE | 32.54 | 0.45 | 0.85 | 67706 |
| 2025-11-18 | RARE | 32.83 | 0.44 | 0.05 | 67749 |
| 2025-11-19 | RARE | 31.86 | 0.44 | 0.57 | 67861 |
| 2025-11-20 | RARE | 31.2 | 0.44 | 0.69 | 67838 |
| 2025-11-21 | RARE | 33.59 | 0.45 | 0.03 | 68063 |
| 2025-11-24 | RARE | 32.79 | 0.44 | 0.58 | 61037 |
| 2025-11-25 | RARE | 33.53 | 0.45 | 0.33 | 61782 |
| 2025-11-26 | RARE | 33.75 | 0.49 | 0.18 | 65014 |
| 2025-12-01 | RARE | 33.37 | 0.49 | 0.46 | 64775 |
| 2025-12-02 | RARE | 33.46 | 0.49 | 0.00 | 64822 |
| 2025-12-03 | RARE | 36.49 | 0.49 | 0.56 | 64932 |
| 2025-12-04 | RARE | 36.54 | 0.48 | 0.44 | 67107 |
| 2025-12-05 | RARE | 36.37 | 0.49 | 0.05 | 67662 |
| 2025-12-08 | RARE | 36.44 | 0.48 | 0.50 | 68775 |
| 2025-12-09 | RARE | 36.28 | 0.48 | 0.42 | 68761 |
| 2025-12-10 | RARE | 35.99 | 0.48 | 0.43 | 69196 |
| 2025-12-11 | RARE | 36.18 | 0.48 | 0.41 | 72429 |
| 2025-12-12 | RARE | 36.22 | 0.48 | 0.05 | 72827 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-13 | RARE | 32.89 | 13.8 | -32.1 | -5.71 |
| 2025-11-14 | RARE | 33.05 | 13.8 | -46.9 | -5.71 |
| 2025-11-17 | RARE | 32.53 | 13.8 | -33.7 | -5.71 |
| 2025-11-18 | RARE | 32.81 | 9.1 | -60.2 | -5.78 |
| 2025-11-19 | RARE | 31.86 | 9.1 | -35.6 | -5.78 |
| 2025-11-20 | RARE | 31.18 | 11.9 | -41.2 | -5.78 |
| 2025-11-21 | RARE | 33.59 | 11.9 | -94.3 | -5.80 |
| 2025-11-24 | RARE | 32.79 | 11.5 | -28.9 | -5.77 |
| 2025-11-25 | RARE | 33.53 | 11.5 | -58.4 | -5.77 |
| 2025-11-26 | RARE | 33.76 | 11.5 | -48.7 | -5.77 |
| 2025-12-01 | RARE | 33.37 | 11.5 | - | -5.77 |
| 2025-12-02 | RARE | 33.47 | 11.5 | - | -5.77 |
| 2025-12-03 | RARE | 36.45 | 11.5 | - | -5.77 |
| 2025-12-04 | RARE | 36.54 | 11.5 | - | -5.77 |
| 2025-12-05 | RARE | 36.38 | 11.5 | - | -5.77 |
| 2025-12-08 | RARE | 36.45 | 11.5 | - | -5.77 |
| 2025-12-09 | RARE | 36.30 | 11.5 | - | -5.77 |
| 2025-12-10 | RARE | 35.98 | 11.5 | - | -5.77 |
| 2025-12-11 | RARE | 36.19 | 11.5 | - | -5.77 |
| 2025-12-12 | RARE | 36.22 | 11.5 | - | -5.77 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-13 | RARE | -0.19 | 4.99 | 7.97 |
| 2025-11-14 | RARE | -0.19 | 4.99 | 7.94 |
| 2025-11-17 | RARE | -0.20 | 5.72 | 7.96 |
| 2025-11-18 | RARE | -0.19 | 5.72 | 7.96 |
| 2025-11-19 | RARE | -0.19 | 5.72 | 7.96 |
| 2025-11-20 | RARE | -0.19 | 5.72 | 7.96 |
| 2025-11-21 | RARE | -0.19 | 5.72 | 7.96 |
| 2025-11-24 | RARE | -0.19 | 2.52 | 7.96 |
| 2025-11-25 | RARE | -0.19 | 2.52 | 7.96 |
| 2025-11-26 | RARE | -0.19 | 2.52 | 8.72 |
| 2025-12-01 | RARE | -0.19 | 2.26 | 8.72 |
| 2025-12-02 | RARE | -0.19 | 2.26 | 8.72 |
| 2025-12-03 | RARE | -0.19 | 2.26 | 8.72 |
| 2025-12-04 | RARE | -0.19 | 2.26 | 8.72 |
| 2025-12-05 | RARE | -0.19 | 2.26 | 8.72 |
| 2025-12-08 | RARE | -0.19 | 2.64 | 8.72 |
| 2025-12-09 | RARE | -0.19 | 2.64 | 8.72 |
| 2025-12-10 | RARE | -0.19 | 2.64 | 9.88 |
| 2025-12-11 | RARE | -0.24 | 2.64 | 9.88 |
| 2025-12-12 | RARE | -0.24 | 2.64 | 9.88 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
[stock_market_widget type="chart" template="candlestick" assets="RARE" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]
Last Quarter Act. EPS
-1.81
Avg. EPS Est. Current Quarter
-1.23
Avg. EPS Est. Next Quarter
-1.47
Insider Transactions
-0.24
Institutional Transactions
2.64
Beta
0.12
Average Sales Estimate Current Quarter
188
Average Sales Estimate Next Quarter
172
Fair Value
Quality Score
26
Growth Score
51
Sentiment Score
35
Actual DrawDown %
79.8
Max Drawdown 5-Year %
-85.2
Target Price
81.85
P/E
Forward P/E
PEG
P/S
5.54
P/B
380.81
P/Free Cash Flow
EPS
-5.94
Average EPS Est. Cur. Y
-5.77
EPS Next Y. (Est.)
-4.47
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-91.95
Relative Volume
1.04
Return on Equity vs Sector %
-6357.6
Return on Equity vs Industry %
-6342.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.71
EBIT Estimation
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”RARE” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RARE” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RARE” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RARE” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RARE” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RARE” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RARE” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading